2026 Interim Report
Filed with HKEX · Stock code 2157 · · 57 pages · English
CORPORATE INFORMATION 2 FINANCIAL SUMMARY 4 MANAGEMENT DISCUSSION AND ANALYSIS 5 OTHER INFORMATION 22 INDEPENDENT REVIEW REPORT 27 INTERIM CONDENSED CONSOLIDATED STATEMENT 28 OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME INTERIM CONDENSED CONSOLIDATED STATEMENT 29 OF FINANCIAL POSITION INTERIM CONDENSED CONSOLIDATED STATEMENT 31 OF CHANGES IN EQUITY INTERIM CONDENSED CONSOLIDATED STATEMENT 32 O
Lepu Biopharma Co. Ltd. on 6ix
Earlier from Lepu Biopharma
- BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
- BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC
Later from Lepu Biopharma
- Voluntary announcement four clinical studies selected for presentation at 2026 ESMO congress: CMG901 (AZD0901) clinical trial results selected as LBA for proffered paper presentation at Presidential Symposium, MRG007 clinical trial results selected as LBA for rapid oral presentation, and two other studies selected for rapid oral presentation
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Lepu Biopharma into a list and get an email when it puts out news.
Follow Lepu Biopharma